$GKOS

Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $160.00 ($1.60M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 21, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the pre-arranged nature reduces informational content versus unscheduled sales.

02

Market read

A CFO 10b5-1 sale of about $1.6M is disclosed, which is usually low-signal for fundamentals.

03

What to watch

Insider sales under 10b5-1 often occur regardless of company outlook; without accompanying buys or changes in guidance, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-21 after-hours/late session, with sale dated 2026-07-16.

Background

This is an SEC Form 4 insider transaction by GKOS’s CFO, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS CFO Thurman Alex R. sold 10,000 shares on 2026-07-16 under a pre-arranged 10b5-1 plan for about $1.6M.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other negative company news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and does not disclose new fundamentals.

Market effects

No clear sector read-through from a single CFO 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity-driven under a scheduled 10b5-1 plan, so it should not be interpreted as a negative view on GKOS prospects.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4 (GKOS).

  • Thurman Alex R.

    SVP and Chief Financial Officer who sold 10,000 shares.

  • 10b5-1 plan

    Pre-arranged plan that schedules trades, typically lowering interpretive value.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.